share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/30 16:59
Moomoo AI 已提取核心信息
On April 29, 2024, ProSomnus, Inc., a medical technology company, announced the issuance and sale of an additional $2 million in Senior Secured Convertible Notes due December 6, 2025, to certain existing investors. This follows a previous issuance of the same amount on April 19, 2024. The notes are part of an agreement under an Indenture dated December 6, 2022, and supplemented by two subsequent indentures. The notes, bearing a 9% annual interest rate, are guaranteed by subsidiary guarantors and secured by the company's assets. This financial move comes after the Nasdaq Stock Market LLC filed to delist ProSomnus' common stock and warrants on April 24, 2024, due to non-compliance with certain listing requirements. Since April 18, 2024, the company's securities have been trading over-the-counter under the symbols 'OSAP' and 'OSAPW'. The delisting from Nasdaq is expected to have no practical effect on the current over-the-counter trading.
On April 29, 2024, ProSomnus, Inc., a medical technology company, announced the issuance and sale of an additional $2 million in Senior Secured Convertible Notes due December 6, 2025, to certain existing investors. This follows a previous issuance of the same amount on April 19, 2024. The notes are part of an agreement under an Indenture dated December 6, 2022, and supplemented by two subsequent indentures. The notes, bearing a 9% annual interest rate, are guaranteed by subsidiary guarantors and secured by the company's assets. This financial move comes after the Nasdaq Stock Market LLC filed to delist ProSomnus' common stock and warrants on April 24, 2024, due to non-compliance with certain listing requirements. Since April 18, 2024, the company's securities have been trading over-the-counter under the symbols 'OSAP' and 'OSAPW'. The delisting from Nasdaq is expected to have no practical effect on the current over-the-counter trading.
2024年4月29日，医疗技术公司ProSomnus, Inc. 宣布向某些现有投资者额外发行和出售2025年12月6日到期的200万美元优先担保可转换票据。在此之前，上次于2024年4月19日发行了相同金额的股票。这些票据是2022年12月6日契约协议的一部分，并由随后的两份契约予以补充。这些票据的年利率为9％，由子公司担保人担保，并由公司的资产担保。这一财务举措是在纳斯达克股票市场有限责任公司因不遵守某些上市要求而于2024年4月24日申请将Prosomnus的普通股和认股权证退市之后采取的。自2024年4月18日以来，该公司的证券一直在场外交易，代码为 “OSAP” 和 “OSAPW”。从纳斯达克退市预计不会对当前的场外交易产生任何实际影响。
2024年4月29日，医疗技术公司ProSomnus, Inc. 宣布向某些现有投资者额外发行和出售2025年12月6日到期的200万美元优先担保可转换票据。在此之前，上次于2024年4月19日发行了相同金额的股票。这些票据是2022年12月6日契约协议的一部分，并由随后的两份契约予以补充。这些票据的年利率为9％，由子公司担保人担保，并由公司的资产担保。这一财务举措是在纳斯达克股票市场有限责任公司因不遵守某些上市要求而于2024年4月24日申请将Prosomnus的普通股和认股权证退市之后采取的。自2024年4月18日以来，该公司的证券一直在场外交易，代码为 “OSAP” 和 “OSAPW”。从纳斯达克退市预计不会对当前的场外交易产生任何实际影响。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息